Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Citius Oncology ( (CTOR) ).
On July 17, 2025, Citius Oncology, Inc. conducted a public offering of common stock and warrants following the filing of a prospectus supplement to its registration statement on Form S-1, which was declared effective on July 15, 2025. This filing was necessary to ensure the registration statement remained current with the company’s recent Quarterly Report on Form 10-Q, as Citius Oncology is not yet eligible to incorporate by reference into the Form S-1 registration statement.
The most recent analyst rating on (CTOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Average Trading Volume: 1,932,754
Technical Sentiment Signal: Sell
Current Market Cap: $132.4M
For an in-depth examination of CTOR stock, go to TipRanks’ Overview page.